These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 29221792

  • 1. The serotonin hallucinogen 5-MeO-DMT alters cortico-thalamic activity in freely moving mice: Regionally-selective involvement of 5-HT1A and 5-HT2A receptors.
    Riga MS, Lladó-Pelfort L, Artigas F, Celada P.
    Neuropharmacology; 2018 Nov; 142():219-230. PubMed ID: 29221792
    [Abstract] [Full Text] [Related]

  • 2. The serotonergic hallucinogen 5-methoxy-N,N-dimethyltryptamine disrupts cortical activity in a regionally-selective manner via 5-HT(1A) and 5-HT(2A) receptors.
    Riga MS, Bortolozzi A, Campa L, Artigas F, Celada P.
    Neuropharmacology; 2016 Feb; 101():370-8. PubMed ID: 26477571
    [Abstract] [Full Text] [Related]

  • 3. The natural hallucinogen 5-MeO-DMT, component of Ayahuasca, disrupts cortical function in rats: reversal by antipsychotic drugs.
    Riga MS, Soria G, Tudela R, Artigas F, Celada P.
    Int J Neuropsychopharmacol; 2014 Aug; 17(8):1269-82. PubMed ID: 24650558
    [Abstract] [Full Text] [Related]

  • 4. Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors.
    Jiang XL, Shen HW, Yu AM.
    Neuropharmacology; 2015 Feb; 89():342-51. PubMed ID: 25446678
    [Abstract] [Full Text] [Related]

  • 5. Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice.
    Halberstadt AL, Koedood L, Powell SB, Geyer MA.
    J Psychopharmacol; 2011 Nov; 25(11):1548-61. PubMed ID: 21148021
    [Abstract] [Full Text] [Related]

  • 6. Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine.
    Halberstadt AL.
    Pharmacol Biochem Behav; 2016 Apr; 143():1-10. PubMed ID: 26780349
    [Abstract] [Full Text] [Related]

  • 7. Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats.
    Fantegrossi WE, Harrington AW, Kiessel CL, Eckler JR, Rabin RA, Winter JC, Coop A, Rice KC, Woods JH.
    Pharmacol Biochem Behav; 2006 Jan; 83(1):122-9. PubMed ID: 16460788
    [Abstract] [Full Text] [Related]

  • 8. Structural pharmacology and therapeutic potential of 5-methoxytryptamines.
    Warren AL, Lankri D, Cunningham MJ, Serrano IC, Parise LF, Kruegel AC, Duggan P, Zilberg G, Capper MJ, Havel V, Russo SJ, Sames D, Wacker D.
    Nature; 2024 Jun; 630(8015):237-246. PubMed ID: 38720072
    [Abstract] [Full Text] [Related]

  • 9. Serotonin 5-HT1A, 5-HT2A and dopamine D2 receptors strongly influence prefronto-hippocampal neural networks in alert mice: Contribution to the actions of risperidone.
    Gener T, Tauste Campo A, Alemany-González M, Nebot P, Delgado-Sallent C, Chanovas J, Puig MV.
    Neuropharmacology; 2019 Nov 01; 158():107743. PubMed ID: 31430459
    [Abstract] [Full Text] [Related]

  • 10. The paradox of 5-methoxy-N,N-dimethyltryptamine: an indoleamine hallucinogen that induces stimulus control via 5-HT1A receptors.
    Winter JC, Filipink RA, Timineri D, Helsley SE, Rabin RA.
    Pharmacol Biochem Behav; 2000 Jan 01; 65(1):75-82. PubMed ID: 10638639
    [Abstract] [Full Text] [Related]

  • 11. The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats.
    Krebs-Thomson K, Ruiz EM, Masten V, Buell M, Geyer MA.
    Psychopharmacology (Berl); 2006 Dec 01; 189(3):319-29. PubMed ID: 17013638
    [Abstract] [Full Text] [Related]

  • 12. Dual actions of 5-MeO-DIPT at the serotonin transporter and serotonin 5-HT1A receptor in the mouse striatum and prefrontal cortex.
    Hagino Y, Hall FS, Uhl GR, Sora I, Ikeda K.
    Neuropsychopharmacol Rep; 2021 Mar 01; 41(1):91-101. PubMed ID: 33547882
    [Abstract] [Full Text] [Related]

  • 13. Clozapine Reverses Phencyclidine-Induced Desynchronization of Prefrontal Cortex through a 5-HT(1A) Receptor-Dependent Mechanism.
    Kargieman L, Riga MS, Artigas F, Celada P.
    Neuropsychopharmacology; 2012 Feb 01; 37(3):723-33. PubMed ID: 22012474
    [Abstract] [Full Text] [Related]

  • 14. Enhanced effects of amphetamine but reduced effects of the hallucinogen, 5-MeO-DMT, on locomotor activity in 5-HT(1A) receptor knockout mice: implications for schizophrenia.
    van den Buuse M, Ruimschotel E, Martin S, Risbrough VB, Halberstadt AL.
    Neuropharmacology; 2011 Feb 01; 61(1-2):209-16. PubMed ID: 21501627
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms.
    Jiang XL, Shen HW, Yu AM.
    Pharmacol Rep; 2016 Jun 01; 68(3):608-15. PubMed ID: 26977821
    [Abstract] [Full Text] [Related]

  • 17. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain.
    Bortolozzi A, Díaz-Mataix L, Toth M, Celada P, Artigas F.
    Psychopharmacology (Berl); 2007 Apr 01; 191(3):745-58. PubMed ID: 17265076
    [Abstract] [Full Text] [Related]

  • 18. [On the Functional Cross-Talk between Brain 5-HT1A and 5-HT2A Receptors].
    Naumenko VS, Bazovkina DV, Kondaurova EM.
    Zh Vyssh Nerv Deiat Im I P Pavlova; 2015 Apr 01; 65(2):240-7. PubMed ID: 26080602
    [Abstract] [Full Text] [Related]

  • 19. Contribution of serotonin receptor subtypes to hallucinogenic activity of 25I-NBOMe and to its effect on neurotransmission.
    Herian M, Wojtas A, Sobocińska MK, Skawski M, González-Marín A, Gołembiowska K.
    Pharmacol Rep; 2020 Dec 01; 72(6):1593-1603. PubMed ID: 33174181
    [Abstract] [Full Text] [Related]

  • 20. Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors.
    Halberstadt AL, Buell MR, Masten VL, Risbrough VB, Geyer MA.
    Psychopharmacology (Berl); 2008 Nov 01; 201(1):55-66. PubMed ID: 18604652
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.